STRS Ohio’s Outlook Therapeutics OTLK Stock Holding History

STRS Ohio’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,350	Closed	-$36K	–	2219
2021 Q4	$36K	Hold	1,350	–	–	﹤0.01%	2052
2021 Q3	$58K	Buy	1,350 +335	+33%	+$16.2K	﹤0.01%	2048
2021 Q2	$50K	Buy	+1,015	New	+$47.1K	﹤0.01%	2108

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vista Finance Clayton, Missouri $179M AUM 18.59% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

STRS Ohio's OTLK Position: Q1 2022 in Review

STRS Ohio sold out of Outlook Therapeutics (OTLK) in Q1 2022, closing a stake of 1,350 shares — an estimated $36K sold.

STRS Ohio first reported a position in OTLK in Q2 2021 and held it in 3 quarters. The position peaked at $58K in Q3 2021. 73 funds tracked by Wall St. Rank hold OTLK as of Q1 2022.

STRS Ohio reported no remaining Outlook Therapeutics position as of Q1 2022 after selling out during the quarter.
STRS Ohio sold 1,350 Outlook Therapeutics shares in Q1 2022, an estimated $36K.
STRS Ohio first reported a position in Outlook Therapeutics in Q2 2021 and held it in 3 quarters.
STRS Ohio's Outlook Therapeutics position peaked at $58K in Q3 2021.
73 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2022.

Based on STRS Ohio's 13F filing for Q1 2022, filed 21 Apr 2022.